15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $65M | -$82M | 0.0% | -130.7% | -$32M | — | $32M |
| 2024 | $68M | -$116M | 0.0% | -179.9% | -$97M | — | $37M |
| 2023 | $79M | -$134M | 0.0% | -173.2% | -$112M | — | $85M |
| 2022 | $86M | -$122M | 0.0% | -143.7% | -$87M | — | $44M |
| 2021 | $97M | -$79M | 0.0% | -112.9% | -$71M | — | $57M |
| 2020 | $122M | -$36M | 0.0% | -34.0% | $6M | — | $87M |
| 2019 | $205M | $46M | 0.0% | 17.9% | $66M | — | $51M |
| 2018 | $207M | $72M | 0.0% | 42.7% | $26M | — | $64M |
| 2017 | $103M | $18M | 0.0% | 23.9% | $50M | — | $66M |
| 2016 | $88M | $22M | 0.0% | 34.9% | $31M | — | $17M |
| 2015 | — | $79M | — | — | — | — | $22M |
| 2014 | — | $34M | — | — | — | — | $31M |
| 2013 | — | $10M | — | — | $10M | — | $9M |
| 2012 | — | $21M | — | — | $22M | — | $11M |
| 2011 | — | $23M | — | — | $24M | — | $7M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $17M | -$13M | 0.0% | -69.1% | -$7M | — | $35M |
| Dec '25 | $19M | -$12M | 0.0% | -60.5% | -$12M | — | $37M |
| Sep '25 | $15M | -$19M | 0.0% | -121.6% | -$8M | — | $32M |
| Jun '25 | $18M | -$18M | 0.0% | -103.2% | $17M | — | $45M |
| Mar '25 | $15M | -$23M | 0.0% | -164.3% | -$16M | — | $60M |
| Dec '24 | $17M | -$22M | 0.0% | -138.8% | -$26M | — | $84M |
| Sep '24 | $15M | -$29M | 0.0% | -204.4% | -$19M | — | $37M |
| Jun '24 | $18M | -$23M | 0.0% | -134.6% | -$21M | — | $36M |
| Mar '24 | $17M | -$31M | 0.0% | -192.1% | -$30M | — | $64M |
| Dec '23 | $18M | -$33M | 0.0% | -193.8% | -$26M | — | $40M |
| Sep '23 | $19M | -$28M | 0.0% | -163.9% | -$23M | — | $85M |
| Jun '23 | $19M | -$39M | 0.0% | -194.3% | -$34M | — | $95M |
| Mar '23 | $18M | -$38M | 0.0% | -221.7% | -$16M | — | $73M |
| Dec '22 | $24M | -$29M | 0.0% | -127.3% | -$39M | — | $42M |
| Sep '22 | $20M | -$26M | 0.0% | -133.1% | -$17M | — | $44M |
| Jun '22 | $19M | -$32M | 0.0% | -167.1% | -$30M | — | $28M |
| Mar '22 | $19M | -$34M | 0.0% | -180.8% | -$26M | — | $41M |
| Dec '21 | $28M | -$30M | 0.0% | -110.0% | -$14M | — | $99M |
| Sep '21 | $24M | -$25M | 0.0% | -143.1% | -$21M | — | $57M |
| Jun '21 | $22M | -$24M | 0.0% | -156.5% | -$30M | — | $5M |
How the market has priced ENTA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Enanta Pharmaceuticals Inc's revenue has declined 11.8% per year. These are computed facts, not advice.
As of FY2025, Enanta Pharmaceuticals Inc reported — of total debt against $32M of cash; operating income covered interest expense -11.1×.
In FY2025, gross margin was —, operating margin -130.7%, and net margin -125.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.